1. The Biotechnology Innovation Organization, which lobbies on behalf of biotech firms, launched an ad campaign to defend drugmakers under scrutiny for their pricing practices. BIO plans to spend between $1 million and $5 million on the campaign. (Bloomberg)
2. An experimental three-in-one inhaled drug developed by GlaxoSmithKline to treat chronic obstructive pulmonary disease reduced flare-ups in patients. AstraZeneca and Novartis are developing similar products. (Reuters)
3. The New York attorney general said his office is investigating whether Mylan unfairly limited competition for its EpiPen allergy injector, the price of which has been hiked substantially in recent years. The drugmaker may have used “potentially anticompetitive terms” in its sales contracts with schools. (AP)
4. Massachusetts public health officials are testing new ways to promote the use of Gilead Sciences’ Truvada as pre-exposure prophylaxis, or PrEP. It is working with AIDS service agencies, health centers, and the Planned Parenthood League of Massachusetts. (Boston Globe)
5. Researchers are developing dust-sized implantable wireless sensors to monitor and treat health conditions. The devices are currently being tested in rats and may be tested in humans within two years. (Reuters)
